SCHEMBL4089272

SCHEMBL4089272

C[C@@H](O[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)[C@H](NCC(=O)O)c1cc(F)c(F)c(F)c1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.32
CASP3 P42574 1/20 0.32
CASP6 P55212 1/20 0.32
CASP8 Q14790 1/20 0.32
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
LMNA P02545 2/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PDPK1 O15530 1/20 0.31
PDCD1 Q15116 1/20 0.31
CD274 Q9NZQ7 1/20 0.31
PTGS1 P23219 3/20 0.30
PTGS2 P35354 2/20 0.30
FABP2 P12104 1/20 0.30
TSHR P16473 1/20 0.30
AKR1C4 P17516 1/20 0.30
ADRA2B P18089 1/20 0.30
CHRM3 P20309 1/20 0.30
HTR2C P28335 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4089068 0.88 LMNA (0.35) TRPM8MEN1KMT2ALMNAHTT
SCHEMBL3626795 0.86 PDPK1 (0.32) MEN1KMT2ASMN1; SMN2PDPK1
SCHEMBL3626801 0.86 PDPK1 (0.32) MEN1KMT2ASMN1; SMN2PDPK1
SCHEMBL4088420 0.86 PTGS1 (0.31) MEN1KMT2ALMNAPTGS1PTGS2
SCHEMBL3627226 0.84 S1PR3 (0.38) LMNAHTTTSHRMAPTHPGD
SCHEMBL3627770 0.75 TACR1 (0.35) TRPM8
SCHEMBL5873085 0.69 PTGS2 (0.35) KMT2APTGS1PTGS2CYP1A2CYP2C9
SCHEMBL8892064 0.69 PTGS2 (0.35) KMT2APTGS1PTGS2CYP1A2CYP2C9
SCHEMBL3754571 0.68 MAPT (0.38) MEN1KMT2AHTTSMN1; SMN2TSHR
SCHEMBL3777347 0.68 MAPT (0.40) MAPTCYP2C19HIF1AFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618960-B2 Morpholine type cinnamide compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-11-17 US disclosed
US-20090203697-A1 HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-08-13 US disclosed
EP-2019094-A1 HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2009-01-28 EP disclosed
EP-1953154-A1 MORPHOLINE TYPE CINNAMIDE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2008-08-06 EP disclosed
US-20070117798-A1 Morpholine type cinnamide compound EISAI R&D MANAGEMENT CO., LTD. 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117798-A1 Morpholine type cinnamide compound MLX, XDH, NOX4 TRPM8 206/4885CASP3 1008/4885CASP6 1004/4885
US-20090203697-A1 HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE CLIC4, NR3C2, MAN2B1 TRPM8 717/4885CASP3 2170/4885CASP6 2663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.